Related Experiment Video
Updated: Jul 31, 2026
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
Published on: March 17, 2014
Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current
Kana Sakamoto1,2, Kengo Takeuchi1,2,3
1Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Insights
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare cancer. Accurate diagnosis is crucial, especially with new treatments, and this review details diagnostic challenges and differential diagnoses like mature plasmacytoid dendritic cell proliferation.
Area of Science:
- Hematologic Malignancies
- Immunology
- Oncology
Background:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with challenging diagnoses due to overlapping features with other leukemias.
- The advent of targeted therapies like tagraxofusp necessitates precise BPDCN identification.
Purpose of the Study:
- To review the clinical, histopathological, and diagnostic criteria for BPDCN.
- To discuss challenges in BPDCN diagnosis, including minimal residual disease detection and differential diagnoses.
- To highlight genetic alterations aiding BPDCN diagnosis.
Main Methods:
- Review of clinical and histopathological features of BPDCN.
- Analysis of diagnostic criteria using flow cytometry and immunohistochemistry.
- Examination of genetic rearrangements (MYC, MYB) and differential diagnoses (MPDCP, pDC-AML).
Main Results:
- BPDCN diagnosis is complex, requiring careful evaluation of morphology, immunophenotype, and genetics.
- Minimal residual disease detection and differentiation from entities like mature plasmacytoid dendritic cell proliferation (MPDCP) and pDC-AML are critical.
- Recurrent 8q24 (MYC) and MYB rearrangements are noted in BPDCN.
Conclusions:
- Accurate diagnosis of BPDCN remains challenging due to its rarity and overlap with other hematologic neoplasms.
- Understanding differential diagnoses, including MPDCP and pDC-AML, is essential for appropriate patient management.
- Novel therapies emphasize the need for refined diagnostic strategies for BPDCN.
Abstract:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy composed of immature cells that exhibit plasmacytoid dendritic cell (pDC) differentiation. The diagnosis of BPDCN is often challenging due to its rarity and morphologic and phenotypic overlap with other hematologic malignancies, such as acute myeloid leukemia (AML). The emergence of tagraxofusp, a CD123-directed cytotoxin, and other novel therapies has underscored the importance of accurately diagnosing BPDCN. This review initially outlined the clinical and histopathological features of BPDCN, including patients with immunoblastoid morphology. Various proposed diagnostic criteria based on flow cytometry and immunohistochemistry findings were presented, highlighting critical points of caution in the diagnostic process. Strategies for detecting minimal residual disease or microinvasion in BPDCN, a significant clinical issue, were also discussed. Additionally, we reviewed the recurrent 8q24 (MYC) and MYB rearrangements observed in BPDCN, which can aid in diagnosis. Furthermore, we explored mature plasmacytoid dendritic cell proliferation (MPDCP) associated with myeloid neoplasm, which is characterized by a clonal proliferation of pDCs in cases with a defined myeloid neoplasm and may also serve as a potential differential diagnosis for BPDCN. Lastly, we discussed pDC-AML, characterized by pDC proliferation in AML cases, which can also be part of MPDCP and is often associated with frequent RUNX1 mutations. Overall, this review provides insights into BPDCN diagnosis and highlights the current challenges in its detection and differential diagnosis.
More Related Videos
Related Concept Videos
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:10Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...
01:15Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
01:26Sputum Studies I: Gram Stain, cytology, and Acid-fast smear and culture
Gram Stain
The Gram Stain is an integral part of sputum studies. It involves the staining of sputum, which permits...
01:19Pericarditis II: Clinical Features and Diagnostic Tests